Nrx Pharmaceuticals Inc (NRXP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -25,126 | -16,048 | -14,425 | -6,528 | -30,150 |
| Depreciation Amortization | 5 | 4 | 2 | 1 | 5 |
| Other Working Capital | 5,291 | 5,377 | 5,334 | 2,287 | 5,164 |
| Other Operating Activity | 9,193 | 2,128 | 2,856 | 569 | 3,324 |
| Operating Cash Flow | $-10,637 | $-8,539 | $-6,233 | $-3,671 | $-21,657 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | N/A | N/A | N/A | N/A | -3 |
| Investing Cash Flow | $N/A | $N/A | $N/A | $N/A | $-3 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 7,079 | 2,941 | N/A | N/A | 943 |
| Debt Repayment | -8,575 | -4,800 | -2,156 | -2,155 | -4,035 |
| Common Stock Issued | 5,911 | 5,911 | 5,692 | 2,550 | 8,122 |
| Other Financing Activity | 3,070 | 1,538 | 0 | 0 | 1,171 |
| Financing Cash Flow | $7,485 | $5,590 | $3,536 | $395 | $6,201 |
| Beginning Cash Position | 4,595 | 4,595 | 4,595 | 4,595 | 20,054 |
| End Cash Position | 1,443 | 1,646 | 1,898 | 1,319 | 4,595 |
| Net Cash Flow | $-3,152 | $-2,949 | $-2,697 | $-3,276 | $-15,459 |
| Free Cash Flow | |||||
| Operating Cash Flow | -10,637 | -8,539 | -6,233 | -3,671 | -21,657 |
| Capital Expenditure | N/A | N/A | N/A | N/A | -3 |
| Free Cash Flow | -10,637 | -8,539 | -6,233 | -3,671 | -21,660 |